17.64
Schlusskurs vom Vortag:
$19.53
Offen:
$19.45
24-Stunden-Volumen:
4.36M
Relative Volume:
2.69
Marktkapitalisierung:
$1.76B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-9.7431
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
-24.05%
1M Leistung:
-33.05%
6M Leistung:
-24.67%
1J Leistung:
-46.00%
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie BEAM mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BEAM
Beam Therapeutics Inc
|
17.64 | 1.76B | 352.57M | -143.01M | -153.40M | -1.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2022-12-13 | Eingeleitet | Citigroup | Buy |
2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
2022-01-05 | Eingeleitet | Guggenheim | Buy |
2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
2021-09-24 | Fortgesetzt | Stifel | Buy |
2021-09-10 | Eingeleitet | BofA Securities | Buy |
2021-05-11 | Eingeleitet | Redburn | Buy |
2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-01-06 | Eingeleitet | Stifel | Hold |
2020-08-05 | Eingeleitet | William Blair | Outperform |
2020-03-02 | Eingeleitet | Barclays | Overweight |
2020-03-02 | Eingeleitet | JP Morgan | Overweight |
2020-03-02 | Eingeleitet | Jefferies | Buy |
2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Beam Therapeutics Becomes Oversold - Nasdaq
Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? - Yahoo Finance
8 Best Gene-Editing Stocks to Buy - Insider Monkey
Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles By Investing.com - Investing.com South Africa
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN
Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus
B of A Securities Upgrades Beam Therapeutics (BEAM) - MSN
Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
B of A Securities Upgrades Beam Therapeutics (BMV:BEAM) - Nasdaq
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock - Benzinga
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target - Investing.com Canada
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target By Investing.com - Investing.com South Africa
BofA Securities Upgrades Beam Therapeutics to Buy From Neutral - Marketscreener.com
FDA Clears Beam Therapeutics' (BEAM) Drug for Genetic Disease Tr - GuruFocus
Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S. - Seeking Alpha
Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance - Marketscreener.com
Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial - Investing.com India
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration - The Manila Times
Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial By Investing.com - Investing.com Australia
Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) By The United States (U.S.) Food And Drug Administration - Marketscreener.com
Beam Therapeutics Announces Clearance of Investigational - GlobeNewswire
Breakthrough: FDA Green Lights Beam's Revolutionary Gene Editing Drug for Rare Disease - Stock Titan
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Beam Therapeutics stock holds firm with $37 target at Bernstein By Investing.com - Investing.com South Africa
Cathie Wood’s ARK focuses on Beam Therapeutics, Intuitive Machines stock - Investing.com
Beam Therapeutics stock holds firm with $37 target at Bernstein - Investing.com
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy - Seeking Alpha
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) - The Globe and Mail
Beam Therapeutics’ $500 Million Common Stock Offering - Global Legal Chronicle
Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily
Prime sets sights on liver, lung disease as next target for its gene editing tech - BioPharma Dive
3 Gene Therapy Stocks to Watch Amid Industry Turmoil - Schaeffers Research
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study - MSN
Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years? - Insider Monkey
BEAM Down Despite Positive Initial Data From Genetic Disorder Study - MSN
Wedbush Research Analysts Raise Earnings Estimates for BEAM - Defense World
Critical Survey: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Beam Therapeutics (NASDAQ:BEAM) - Defense World
Citi lifts Beam Therapeutics stock price target to $64 - Investing.com India
Citi lifts Beam Therapeutics stock price target to $64 By Investing.com - Investing.com South Africa
Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock By Investing.com - Investing.com South Africa
Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock - Investing.com Australia
Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial - CRISPR Medicine News
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):